SK Chemicals and Tegoscience Jointly Market Cell Therapy for Diabetic Foot

[Asia Economy Reporter Cho Hyun-ui] SK Chemicals announced on the 14th that it has signed a joint marketing agreement with general hospitals for 'Kaloderm,' a burn and diabetic foot ulcer (diabetic foot) cell therapy developed by TegoScience, a cell therapy specialist company.

Through joint marketing of Kaloderm, SK Chemicals plans to expand its portfolio into the diabetic complications sector. TegoScience expects to strengthen its position in the diabetic foot market based on SK Chemicals' marketing capabilities in general hospitals.

Kaloderm is the most widely used cell therapy product currently in use in Korea. Unlike most cell therapies, it is characterized by its ability for mass production and long-term frozen storage.

Kim Jung-hoon, head of SK Chemicals Center, stated, "We plan to continuously expand our product portfolio in the surgical field and diabetic complications sector."